Oxaliplatin with Chemotherapy Improves Disease-Free Survival in Patients with Colon Cancer
Colon Cancer Treatment
New data presented today by researchers from Allegheny General Hospital (AGH) and the Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project (NSABP) show that combining the drug oxaliplatin to the conventional chemotherapy regimen of 5-FU plus leucovorin significantly improves disease-free survival in patients with stage II or III colon cancer. The results were announced at the annual meeting of the American Society of Clinical Oncology (ASCO). Support for the study was provided by the National Cancer Institute (NCI).
"This is good news. These results will influence the standard of care for stage II and III patients with colon cancer," said Norman Wolmark, MD, chairman of both the Department of Human Oncology at AGH and the NSABP.